HuGE Literature Finder
Records
1
-
3
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab. British journal of haematology 2018 Sep . Cencini Emanuele, Sicuranza Anna, Fabbri Alberto, Ferrigno Ilaria, Rigacci Luigi, Cox Maria C, Raspadori Donatella, Bocchia Moni |
FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC research notes 2014 7 (1): 260. Bécouarn Yves, Cany Laurent, Pulido Marina, Beyssac Richard, Texereau Patrick, Le Morvan Valérie, Béchade Dominique, Brunet René, Aitouferoukh Sofiane, Lalet Caroline, Mathoulin-Pélissier Simone, Fonck Marianne, Robert Jacqu |
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. Investigational new drugs 2012 Nov . Infante JR, Novello S, Ma WW, Dy GK, Bendell JC, Huff A, Wang Q, Suttle AB, Allen R, Xu CF, Ottesen LH, Burris HA, Adjei AA |
- Page last reviewed:Oct 1, 2021
- Page last updated:May 25, 2022
- Content source: